Collegium Pharmaceutical, Inc. (COLL)
25.35
-1.09
(-4.12%)
USD |
NASDAQ |
Aug 28, 16:00
25.35
0.00 (0.00%)
After-Hours: 20:00
Collegium Pharmaceutical Free Cash Flow : 328.28M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 328.28M |
| March 31, 2026 | 329.83M |
| December 31, 2025 | 327.58M |
| September 30, 2025 | 289.30M |
| June 30, 2025 | 201.80M |
| March 31, 2025 | 196.56M |
| December 31, 2024 | 203.33M |
| September 30, 2024 | 192.43M |
| June 30, 2024 | 275.62M |
| March 31, 2024 | 308.16M |
| December 31, 2023 | 274.29M |
| September 30, 2023 | 266.50M |
| June 30, 2023 | 235.20M |
| March 31, 2023 | 175.53M |
| December 31, 2022 | 122.61M |
| September 30, 2022 | 92.91M |
| June 30, 2022 | 67.23M |
| March 31, 2022 | 56.05M |
| December 31, 2021 | 101.61M |
| September 30, 2021 | 87.03M |
| June 30, 2021 | 101.82M |
| March 31, 2021 | 114.63M |
| Date | Value |
|---|---|
| December 31, 2020 | -279.83M |
| September 30, 2020 | -286.16M |
| June 30, 2020 | -313.22M |
| March 31, 2020 | -341.08M |
| December 31, 2019 | 21.34M |
| September 30, 2019 | 47.09M |
| June 30, 2019 | 81.49M |
| March 31, 2019 | 122.71M |
| December 31, 2018 | 145.15M |
| September 30, 2018 | 91.17M |
| June 30, 2018 | 39.14M |
| March 31, 2018 | -33.74M |
| December 31, 2017 | -68.01M |
| September 30, 2017 | -78.17M |
| June 30, 2017 | -84.79M |
| March 31, 2017 | -90.23M |
| December 31, 2016 | -78.03M |
| September 30, 2016 | -61.19M |
| June 30, 2016 | -48.36M |
| March 31, 2016 | -29.43M |
| December 31, 2015 | -21.93M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Innoviva, Inc. | 189.44M |
| Zevra Therapeutics, Inc. | 32.62M |
| Supernus Pharmaceuticals, Inc. | 18.79M |
| Indivior Pharmaceuticals, Inc. | -119.51M |
| Crinetics Pharmaceuticals, Inc. | -425.18M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 71.32M |
| Cash from Investing (Quarterly) | -502.59M |
| Cash from Financing (Quarterly) | 292.09M |
| Free Cash Flow Per Share (Quarterly) | 2.182 |
| Free Cash Flow to Equity (Quarterly) | -217.36M |
| Free Cash Flow to Firm (Quarterly) | 92.54M |
| Free Cash Flow Yield | 34.07% |